论文部分内容阅读
氨苯蝶啶(以下简称TA)为有显著钾潴留作用的缓和利尿剂,与强利尿剂伍用可减少后者排钾的副作用。作者对32名不同程度的肾衰患者进行了TA及其主要活性代谢物羟基硫酸酯(以下简称OH-TA-酯)的药代动力学研究。所有受试者于上午8时空腹口服TA100mg,然后,按时收集尿液和采血。 TA及OH-TA-酯用薄层色谱荧光测定法测定。蛋白结合用超滤及平衡透析技术测定。肾清除率、血浆浓度-时间曲线下面积(AUC)用梯形刻度尺测量,由累积尿排泄量与AUC之比得出药物的肾清除事。肾清除率与内生肌酐清除率的相关性用电子计算机计算。
Triamterene (hereinafter referred to as TA) is a mitigating diuretic with significant potassium retention, and strong diuretics with Wu side can reduce the latter row of potassium side effects. The author of 32 patients with varying degrees of renal failure were TA and its main active metabolite hydroxysulfate (hereinafter referred to as OH-TA-ester) pharmacokinetic studies. All subjects oral TA100mg orally at 8 am, then, on time collection of urine and blood collection. TA and OH-TA-esters were determined by thin layer chromatography fluorimetry. Protein binding was determined by ultrafiltration and equilibrium dialysis. The area under the renal clearance, plasma concentration-time curve (AUC) was measured with a trapezoidal scale and the renal clearance of the drug was derived from the cumulative urinary excretion to AUC ratio. The correlation between renal clearance and endogenous creatinine clearance was calculated using a computer.